Organisation paid for research Program year 2025 Source: CMS Open Payments

Henry Ford Health

Neither a doctor nor a teaching hospital

Research payments

$619,789

48 payments

Through program year 2025, Henry Ford Health is reported as receiving $619,789 in research payments, across 48 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $191,985 16
2024 Research $133,187 7
2023 Research $278,481 20
2022 Research $16,136 5

Breakdown

Who paid Research payments · program years 2022–2025
  1. Novartis Pharmaceuticals Corporation $572,501 38 payments
  2. Stryker Corporation $30,276 4 payments
  3. Zimmer Biomet Holdings, Inc. $16,014 4 payments
  4. Roche Diagnostics Corporation $876 1 payment
  5. E.R. Squibb & Sons, L.L.C. $122 1 payment
Studies the money was for Research payments · program years 2022–2025
  1. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $143,178 5 payments
  2. A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2Nd Line Chronic Phase - Chronic Myelogenous Leukemia $102,066 3 payments
  3. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $99,604 1 payment
  4. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $47,687 4 payments
  5. A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] $37,319 1 payment
  6. Defiance - Clottriever Thrombectomy System VS. Anticoagulation Alone for Treatment of Deep Vein Thrombosis $30,276 4 payments
  7. A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3) $28,077 1 payment
  8. A Subject and Investigator Blinded, Randomized, Placebo-Controlled, Repeat-Dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of Cmk389 in Patients With Chronic Pulmonary Sarcoidosis $25,985 1 payment
  9. A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL $23,653 1 payment
  10. ROSA Total Knee Post Market Study $16,014 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record